EcoDrugPlus

Yes Proto-Oncogene 1, Src Family Tyrosine Kinase

Ensembl ID : ENSATEG00000004191
Gene Symbol: YES1
3 Cross references
197 Possible Orthologues:

Activin A Receptor Type 2ba

Ensembl ID : ENSATEG00000015442
Gene Symbol: ACVR2BA
1 Cross references
193 Possible Orthologues:

Activin A Receptor Type 2ba

Ensembl ID : ENSATEG00000015480
Gene Symbol: ACVR2BA
1 Cross references
193 Possible Orthologues:

Activin Receptor Type-2b-Like

Ensembl ID : ENSATEG00000020311
Gene Symbol: LOC113172399
2 Cross references
196 Possible Orthologues:

Adenosine A1 Receptor B

Ensembl ID : ENSATEG00000020216
Gene Symbol: ADORA1B
2 Cross references
201 Possible Orthologues:

Adenosine A2a Receptor A

Ensembl ID : ENSATEG00000014104
Gene Symbol: ADORA2AA
3 Cross references
188 Possible Orthologues:

Adenosine A2b Receptor

Ensembl ID : ENSATEG00000029624
Gene Symbol: ADORA2B
3 Cross references
199 Possible Orthologues:

Adenosine Deaminase

Ensembl ID : ENSATEG00000024562
Gene Symbol: ADA
3 Cross references
219 Possible Orthologues:

Adenosine Receptor A1-Like

Ensembl ID : ENSATEG00000025088
Gene Symbol: LOC113153463
2 Cross references
234 Possible Orthologues:

Adenosine Receptor A1-Like

Ensembl ID : ENSATEG00000024238
Gene Symbol: LOC113155069
2 Cross references
208 Possible Orthologues:

Adhesion Regulating Molecule 1

Ensembl ID : ENSATEG00000024777
Gene Symbol: ADRM1
2 Cross references
197 Possible Orthologues:

Adrenoceptor Alpha 1aa

Ensembl ID : ENSATEG00000022658
Gene Symbol: ADRA1AA
1 Cross references
202 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).